Loss of CDKN2A at chromosome 9 has a poor clinical prognosis and promotes lung cancer progression-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Loss of CDKN2A at chromosome 9 has a poor clinical prognosis and promotes lung cancer progression

Published:2020-11-06 Issue:12 Volume:8 Page:
ISSN:2324-9269
Container-title:Molecular Genetics & Genomic Medicine
language:en
Short-container-title:Mol. Genet. Genomic Med.

Author:

Liu Wei¹,Zhuang Congwen¹,Huang Tengfei¹,Yang Shengsheng¹,Zhang Meiqing¹,Lin Baoquan²^ORCID,Jiang Yi³

Affiliation:

1. Department of Respiratory and Critical Care Medicine The 900th Hospital of Joint Logistic Support Force Fuzhou Fujian China

2. Department of Thoracic Surgery The 900th Hospital of Joint Logistic Support Force Fuzhou Fujian China

3. Department of Hepatobiliary Surgery The 900th Hospital of Joint Logistic Support Force Fuzhou Fujian China

Publisher

Wiley

Subject

Genetics(clinical),Genetics,Molecular Biology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mgg3.1521

Reference31 articles.

1. Concurrent alteration of p16 and PTEN tumor suppressor genes could be considered as potential molecular marker for specific subgroups of NSCLC patients;Andjelkovic T.;Cancer Biomarkers,2011

2. Lung cancer;Barnett R.;Lancet,2017

3. Growth and Metastases of Human Lung Cancer Are Inhibited in Mouse Xenografts by a Transition State Analogue of 5′-Methylthioadenosine Phosphorylase

4. Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis

5. CDKN2A (p16) Promoter Hypermethylation Influences the Outcome in Young Lung Cancer Patients

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical significance and prospective mechanism of increased CDKN2A expression in small cell lung cancer;Clinical and Translational Oncology;2024-01-11

2. p53 exerts anticancer effects by regulating enhancer formation and activity;The Journal of Biomedical Research;2024

3. Impact of Concurrent Genomic Alterations on Clinical Outcomes in Patients With ALK-Rearranged NSCLC;Journal of Thoracic Oncology;2024-01

4. Tumor Heterogeneity in Breast Cancer Progression;Handbook of Oncobiology: From Basic to Clinical Sciences;2024

5. Malignant and borderline mesothelial tumors of the pleura;Practical Pulmonary Pathology;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3